Efficiency perspectives on adaptive designs in stroke clinical trials

Stroke

Volumn 42, Issue 10, 2011, Pages 2990-2994

  Cheung, Ken ^a   Kaufmann, Petra ^b  

^a Howard Hughes Medical Institute   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

continual reassessment method; futility interim analysis; Internal pilot; prospective planning

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO;

CLINICAL TRIAL (TOPIC); COST; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; HUMAN; MAXIMUM TOLERATED DOSE; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; STROKE;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; RESEARCH DESIGN; STROKE;

EID: 80053314742     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.620765     Document Type: Review

References (27)

1. NINDS rt-PA Stroke Study. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. U.S. Food and Drug Administration. Draft guidance for industry on adaptive design clinical trials for drugs and biologics. http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm201790.pdf. February 2010. Accessed May 31, 2011.
3. Thompson WR. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. Biometrika. 1933;25: 285-294.
4. Stein C. A two-sample test for a linear hypothesis whose power is independent of the variance. Ann Math Stat. 1945;16:243-258.
5. Robbins H, Monro S. A stochastic approximation method. Ann Math Stat. 1951;22:400-407.
6. Zelen M. Play the winner rule and the controlled clinical trials. J Am Stat Assoc. 1969;64:131-146.
7. Armitage P, McPherson K, Rowe BC. Repeated significance tests on accumulating data. J Royal Stat Soc Ser A. 1969;132:235-244.
8. Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc. 1978;73:840-843.
9. Pocock SJ. Group sequential methods in design and analysis of clinical trials. Biometrika. 1977;64:191-200.
10. O'Brien PC, Fleming TR. Multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556. (Pubitemid 10242750)
11. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat in Med. 1990;9:65-72. (Pubitemid 20294367)
12. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50:1029-1041.
13. Coffey CS, Muller KE. Controlling test size while gaining the benefits of an internal pilot design. Biometrics. 2001;57:625-631. (Pubitemid 32488626)
14. Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Stat Med. 2009;28:1181-1217.
15. Cheung YK. Stochastic approximation and modern model-based designs for dose-finding clinical trials. Stat Sci. 2010;25:191-201.
16. Wang SJ. Adaptive designs: Appealing in development of therapeutics, and where do controversies lie? J Biopharm Stat. 2010;20:1083-1087.
17. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development-an executive summary of the PhRMA working group. J Biopharml Stat. 2006;16:275-283.
18. Fisher M, Cheung K, Howard G, Warach S. New pathways for evaluating potential acute stroke therapies. Int J Stroke. 2006;1:52-58.
19. Elkind MSV, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, et al. The Neuroprotection with statin therapy for acute recovery trial (NeuSTART): an adaptive design phase 1 dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke. 2008;3: 210-218.
20. Elkind MSV, Sacco RL, MacArthur RB, Peerschke E, Neils G, Andrews H, et al. High-dose lovastatin for acute ischemic stroke: Results of the phase 1 dose escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART). Cerebrovasc Dis. 2009;3:266-275.
21. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177-1182.
22. Cheung YK. Coherence principles in dose finding studies. Biometrika. 2005;92:863-873. (Pubitemid 41681239)
23. MR Stroke Collaborative Group. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke. 2006;37:2521-2525.
24. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
25. Neyman J, Pearson E. On the problem of the most efficient tests of statistical hypotheses. Philos Trans R Soc Lond B Biol Sci A. 1933;231: 289-337.
26. Cheung YK. Simple sequential boundaries for treatment selection in multi-armed randomized clinical trials with a control. Biometrics. 2008; 64:940-949.
27. Proschan MA, Lan KKG, Wittes JK. Statistical Monitoring of Clinical Trials: A Unified Approach. Ed. New York, NY: Springer; 2006.